Recommendation for <i>TP53</i> mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre-Reference-Cited by-同舟云学术

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre

Published:2022-07 Issue:7 Volume:52 Page:1286-1287
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Tam Constantine S.¹²³^ORCID,Gregory Gareth P.²⁴^ORCID,Ku Matthew⁵⁶^ORCID,Fleming Shaun¹²,Handunnetti Sasanka M.⁷,Lee Denise⁸,Walker Patricia¹⁹¹⁰,Perkins Andrew¹²,Lew Thomas E.⁷¹¹,Sirdesai Shreerang¹²,Chua Chong Chyn¹¹³,Gilbertson Michael²⁴¹⁴,Lasica Masa⁵⁶,Anderson Mary Ann⁷¹¹,Renwick William⁶¹⁴,Grigg Andrew¹⁵,Patil Sush¹²,Opat Stephen²⁴,Friebe Adam¹²,Cooke Rachel¹³,De Boer Jasper³,Spencer Andrew¹²,Ritchie David⁶⁷,Agarwal Rishu¹⁵,Blombery Piers⁶⁷

Affiliation:

1. Alfred Hospital Melbourne Victoria Australia

2. Monash University Melbourne Victoria Australia

3. VCCC Alliance Melbourne Victoria Australia

4. Monash Haematology Monash Health Melbourne Victoria Australia

5. Department of Haematology St Vincent's Hospital Melbourne Victoria Australia

6. University of Melbourne Melbourne Victoria Australia

7. Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia

8. Department of Haematology Box Hill Hospital Melbourne Victoria Australia

9. Department of Clinical Haematology Peninsula Health Melbourne Victoria Australia

10. Peninsula Private Hospital Melbourne Victoria Australia

11. Blood Cells and Blood Cancer Division Walter and Eliza Hall Institute of Medical Research Melbourne Victoria Australia

12. Department of Haematology University Hospital Geelong Geelong Victoria Australia

13. Department of Clinical Haematology Northern Health Melbourne Victoria Australia

14. Department of Haematology and Oncology Western Health Melbourne Victoria Australia

15. Department of Clinical Haematology Austin Hospital Melbourne Victoria Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15851

Reference13 articles.

1. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

2. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

3. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

4. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial

5. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis